|
1.
|
Heinrichs SC, Leite-Morris KA, Guy MD, Goldberg LR, Young AJ, Kaplan GB. Dendritic structural plasticity in the basolateral amygdala after fear conditioning and its extinction in mice. Behav Brain Res. 2013 Jul 1; 248:80-4.
|
|
|
|
|
2.
|
Nic Dhonnchadha BÁ, Lin A, Leite-Morris KA, Kaplan GB, Man HY, Kantak KM. Alterations in expression and phosphorylation of GluA1 receptors following cocaine-cue extinction learning. Behav Brain Res. 2013 Feb 1; 238:119-23.
|
|
|
|
|
3.
|
Nic Dhonnchadha BÁ, Lovascio BF, Shrestha N, Lin A, Leite-Morris KA, Man HY, Kaplan GB, Kantak KM. Changes in expression of c-Fos protein following cocaine-cue extinction learning. Behav Brain Res. 2012 Sep 1; 234(1):100-6.
|
|
|
|
|
4.
|
Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM, Ahnallen CG. Separate and combined effects of very low nicotine cigarettes and nicotine replacement in smokers with schizophrenia and controls. Nicotine Tob Res. 2013 Jan; 15(1):121-9.
|
|
|
|
|
5.
|
Ahnallen CG, Liverant GI, Gregor KL, Kamholz BW, Levitt JJ, Gulliver SB, Pizzagalli DA, Koneru VK, Kaplan GB. The relationship between reward-based learning and nicotine dependence in smokers with schizophrenia. Psychiatry Res. 2012 Mar 30; 196(1):9-14.
|
|
|
|
|
6.
|
Kaplan GB, Leite-Morris KA, Fan W, Young AJ, Guy MD. Opiate Sensitization Induces FosB/?FosB Expression in Prefrontal Cortical, Striatal and Amygdala Brain Regions. PLoS One. 2011; 6(8):e23574.
|
|
|
|
|
7.
|
Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM, Reid N. Effects of contingency management and bupropion on cigarette smoking in smokers with schizophrenia. Psychopharmacology (Berl). 2011 Sep; 217(2):279-87.
|
|
|
|
|
8.
|
Kaplan GB, Moore KA. The use of cognitive enhancers in animal models of fear extinction. Pharmacol Biochem Behav. 2011 Aug; 99(2):217-28.
|
|
|
|
|
9.
|
Kaplan GB, Vasterling JJ, Vedak PC. Brain-derived neurotrophic factor in traumatic brain injury, post-traumatic stress disorder, and their comorbid conditions: role in pathogenesis and treatment. Behav Pharmacol. 2010 Sep; 21(5-6):427-37.
|
|
|
|
|
10.
|
Kaplan GB, Heinrichs SC, Carey RJ. Treatment of addiction and anxiety using extinction approaches: Neural mechanisms and their treatment implications. Pharmacol Biochem Behav. 2011 Jan; 97(3):619-25.
|
|
|
|
|
11.
|
Sirota AD, Rohsenow DJ, Mackinnon SV, Martin RA, Eaton CA, Kaplan GB, Monti PM, Tidey JW, Swift RM. Intolerance for Smoking Abstinence Questionnaire: psychometric properties and relationship to tobacco dependence and abstinence. Addict Behav. 2010 Jul; 35(7):686-93.
|
|
|
|
|
12.
|
Heinrichs SC, Leite-Morris KA, Carey RJ, Kaplan GB. Baclofen enhances extinction of opiate conditioned place preference. Behav Brain Res. 2010 Mar 5; 207(2):353-9.
|
|
|
|
|
13.
|
Kaplan GB, Leite-Morris KA, Klufas MA, Fan W. Intra-VTA adenosine A1 receptor activation blocks morphine stimulation of motor behavior and cortical and limbic Fos immunoreactivity. Eur J Pharmacol. 2009 Jan 14; 602(2-3):268-76.
|
|
|
|
|
14.
|
Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM, Adolfo AB. Effects of smoking abstinence, smoking cues and nicotine replacement in smokers with schizophrenia and controls. Nicotine Tob Res. 2008 Jun; 10(6):1047-56.
|
|
|
|
|
15.
|
Rohsenow DJ, Monti PM, Hutchison KE, Swift RM, MacKinnon SV, Sirota AD, Kaplan GB. High-dose transdermal nicotine and naltrexone: effects on nicotine withdrawal, urges, smoking, and effects of smoking. Exp Clin Psychopharmacol. 2007 Feb; 15(1):81-92.
|
|
|
|
|
16.
|
Kaplan GB, Phillips KA, Vaccaro A, Eisen JL, Posternak MA, MacAskill HS. Assessment of insight into delusional beliefs in schizophrenia using the Brown Assessment of Beliefs Scale. Schizophr Res. 2006 Feb 28; 82(2-3):279-81.
|
|
|
|
|
17.
|
Epstein-Lubow G, Hochstadt J, Lieberman P, Kaplan GB. Speech production in schizophrenia: preliminary data regarding voice onset time. Schizophr Res. 2006 Feb 28; 82(2-3):267-9.
|
|
|
|
|
18.
|
Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM. Cigarette smoking topography in smokers with schizophrenia and matched non-psychiatric controls. Drug Alcohol Depend. 2005 Nov 1; 80(2):259-65.
|
|
|
|
|
19.
|
Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM. Subjective and physiological responses to smoking cues in smokers with schizophrenia. Nicotine Tob Res. 2005 Jun; 7(3):421-9.
|
|
|
|
|
20.
|
Kaplan GB, McRoberts RL, Smokler HJ. Baclofen as adjunctive treatment for a patient with cocaine dependence and schizoaffective disorder. J Clin Psychopharmacol. 2004 Oct; 24(5):574-5.
|
|
|
|
|
21.
|
Turalba AV, Leite-Morris KA, Kaplan GB. Antipsychotics regulate cyclic AMP-dependent protein kinase and phosphorylated cyclic AMP response element-binding protein in striatal and cortical brain regions in mice. Neurosci Lett. 2004 Feb 26; 357(1):53-7.
|
|
|
|
|
22.
|
Leite-Morris KA, Fukudome EY, Shoeb MH, Kaplan GB. GABA(B) receptor activation in the ventral tegmental area inhibits the acquisition and expression of opiate-induced motor sensitization. J Pharmacol Exp Ther. 2004 Feb; 308(2):667-78.
|
|
|
|
|
23.
|
Kaplan GB, Leite-Morris KA, Joshi M, Shoeb MH, Carey RJ. Baclofen inhibits opiate-induced conditioned place preference and associated induction of Fos in cortical and limbic regions. Brain Res. 2003 Oct 10; 987(1):122-5.
|
|
|
|
|
24.
|
Leite-Morris KA, Fukudome EY, Kaplan GB. Opiate-induced motor stimulation is regulated by gamma-aminobutyric acid type B receptors found in the ventral tegmental area in mice. Neurosci Lett. 2002 Jan 14; 317(3):119-22.
|
|
|
|
|
25.
|
Rohsenow DJ, Monti PM, Hutchison KE, Swift RM, Colby SM, Kaplan GB. Naltrexone's effects on reactivity to alcohol cues among alcoholic men. J Abnorm Psychol. 2000 Nov; 109(4):738-42.
|
|
|
|
|
26.
|
Kaplan GB, Greenblatt DJ, Ehrenberg BL, Goddard JE, Harmatz JS, Shader RI. Differences in pharmacodynamics but not pharmacokinetics between subjects with panic disorder and healthy subjects after treatment with a single dose of alprazolam. J Clin Psychopharmacol. 2000 Jun; 20(3):338-46.
|
|
|
|
|
27.
|
Kaplan GB, Leite-Morris KA, Keith DJ. Differential effects of treatment with typical and atypical antipsychotic drugs on adenylyl cyclase and G proteins. Neurosci Lett. 1999 Oct 8; 273(3):147-50.
|
|
|
|
|
28.
|
Kaplan GB, Bharmal NH, Leite-Morris KA, Adams WR. Role of adenosine A1 and A2A receptors in the alcohol withdrawal syndrome. Alcohol. 1999 Oct; 19(2):157-62.
|
|
|
|
|
29.
|
Weisberg SP, Kaplan GB. Adenosine receptor antagonists inhibit the development of morphine sensitization in the C57BL/6 mouse. Neurosci Lett. 1999 Apr 2; 264(1-3):89-92.
|
|
|
|
|
30.
|
Kaplan GB, Coyle TS. Adenosine kinase inhibitors attenuate opiate withdrawal via adenosine receptor activation. Eur J Pharmacol. 1998 Nov 27; 362(1):1-8.
|
|
|
|
|
31.
|
Leite-Morris KA, Kaplan GB, Smith JG, Sears MT. Regulation of G proteins and adenylyl cyclase in brain regions of caffeine-tolerant and -dependent mice. Brain Res. 1998 Aug 31; 804(1):52-62.
|
|
|
|
|
32.
|
Kaplan GB, Sethi RK, McClelland EG, Leite-Morris KA. Regulation of G protein-mediated adenylyl cyclase in striatum and cortex of opiate-dependent and opiate withdrawing mice. Brain Res. 1998 Mar 30; 788(1-2):104-10.
|
|
|
|
|
33.
|
Kaplan GB, Greenblatt DJ, Ehrenberg BL, Goddard JE, Cotreau MM, Harmatz JS, Shader RI. Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans. J Clin Pharmacol. 1997 Aug; 37(8):693-703.
|
|
|
|
|
34.
|
Kaplan GB, Leite-Morris KA. Up-regulation of adenosine transporter-binding sites in striatum and hypothalamus of opiate tolerant mice. Brain Res. 1997 Jul 25; 763(2):215-20.
|
|
|
|
|
35.
|
Kaplan GB, Sears MT. Adenosine receptor agonists attenuate and adenosine receptor antagonists exacerbate opiate withdrawal signs. Psychopharmacology (Berl). 1996 Jan; 123(1):64-70.
|
|
|
|
|
36.
|
Kaplan GB, Leite-Morris KA, Sears MT. Alterations of adenosine A1 receptors in morphine dependence. Brain Res. 1994 Sep 19; 657(1-2):347-50.
|
|
|
|
|
37.
|
Kaplan GB, Greenblatt DJ, Kent MA, Cotreau-Bibbo MM. Caffeine treatment and withdrawal in mice: relationships between dosage, concentrations, locomotor activity and A1 adenosine receptor binding. J Pharmacol Exp Ther. 1993 Sep; 266(3):1563-72.
|
|
|
|
|
38.
|
Kaplan GB. Neurobiological aspects of panic disorder. R I Med. 1992 May; 75(5):247-51.
|
|
|
|
|
39.
|
Kaplan GB, Greenblatt DJ, Kent MA, Cotreau MM, Arcelin G, Shader RI. Caffeine-induced behavioral stimulation is dose-dependent and associated with A1 adenosine receptor occupancy. Neuropsychopharmacology. 1992 May; 6(3):145-53.
|
|
|
|
|
40.
|
Kaplan GB, Tai NT, Greenblatt DJ, Shader RI. Separate and combined effects of caffeine and alprazolam on motor activity and benzodiazepine receptor binding in vivo. Psychopharmacology (Berl). 1990; 101(4):539-44.
|
|
|
|
|
41.
|
Kaplan GB, Greenblatt DJ, Leduc BW, Thompson ML, Shader RI. Relationship of plasma and brain concentrations of caffeine and metabolites to benzodiazepine receptor binding and locomotor activity. J Pharmacol Exp Ther. 1989 Mar; 248(3):1078-83.
|
|
|
|
